Background: The etiology of sudden sensorineural hearing loss (SSNHL) is still unclear and is most probably diverse.
S udden sensorineural hearing loss (SSNHL) is defined as a perceptive hearing loss of 30 dB or more in at least three contiguous frequencies occurring for not more than 3 days. 1 The estimated incidence of 1 case per 5000 to 10 000 2 is probably even higher because many patients who recover spontaneously soon after the onset of SSNHL do not seek medical help. There are many theories regarding the etiology of SSNHL, demonstrating our poor understanding of this entity. Among the most widely accepted are viral, autoimmune, and vascular theories. The facts supporting viral etiology are studies of temporal bones obtained from patients with SSNHL that showed histologic findings similar to those in viral labyrinthitis. 3, 4 Increased levels of antiviral antibodies in patients with SSNHL, 5, 6 especially seroconversion in some of these patients, 1, 6, 7 also support viral theory. The viruses for which elevated antibody levels were found are herpes simplex virus, parotitis virus, influenza and parainfluenza virus, Morbillivirus, and adenovirus. However, the above-mentioned studies were not able to prove the relationship between antibody titre and amount of hearing loss or recovery rate. Against viral theory are a study of magnetic resonance imaging (MRI) of temporal bones in patients with SSNHL, 9 in which no signs of labyrinthitis were found (although this may be because of the low sensitivity of this method), and a study that showed no increase in interferon-α or β-inducible MxA protein in patients with SSNHL (this protein is considered to be a good indicator of systemic viral infection). 10 Autoimmune theory is supported by the occurrence of SSNHL in several autoimmune diseases, such as systemic lupus erythematosus, temporal arteritis, polyarteritis nodosa, and Cogan's syndrome. [11] [12] [13] The finding of antiendothelial antibodies in 53% of patients with SSNHL 14 also favours autoimmune theory, although that study included only 15 patients. The phenotyping of lymphocytes in 22 SSNHL patients showed a decreased number of CD4 + helper and CD8 + cytotoxic lymphocytes, as well as a decreased number of CD4+CD45RA + and CD8 + CD45RA + lymphocyte subpopulations, in comparison with the normal population, pointing to some disorder in the immune system of those patients. 15 Furthermore, a good response to steroid therapy supports the autoimmune etiology of SSNHL, although the results with immunosuppressive agents were not convincing, 16, 17 which leaves autoimmune theory still questionable.
The facts that are the most suggestive for vascular theory are sudden onset of SSNHL resembling vascular insult and the fact that the labyrinthine artery (LA) is the terminal artery, meaning that any occlusion will lead to some loss of function. In addition, the susceptibility of inner ear cells to ischemia is well known and experimentally proved. 18 The occurrence of SSNHL in systemic vascular diseases, such as sickle cell anemia, 19 Waldenström's macroglobulinemia, 20 systemic vasculitis, 21 and cardiopulmonary bypasses (probably as the result of microemboli), 22 also supports vascular theory. There are several reports concerning the influence of vertebrobasilar circulation on inner ear blood flow. It has been demonstrated that unilateral occlusion of the vertebral artery does not change cochlear blood flow in rats, but if systemic hypotension ensues, the cochlear blood flow will significantly decrease. 23 As was demonstrated on guinea pigs, the decrease in cochlear blood flow will lead to functional disturbance of the inner ear, manifested by aberration of cochlear microphonisms and the brainstem evoked response. 24 The direct answer to whether the etiology of SSNHL is vascular would be obtained by measuring blood flow in the LA in patients with SSNHL. There are already several studies of Doppler ultrasonographic measurement of cochlear blood flow, even in patients with SSNHL, 25 but this method is invasive and inconvenient for everyday use. The closest vessels available for noninvasive detection are the vertebral arteries (VAs) and the basilar arteries (BAs). Guttman and colleagues measured cervical blood flow in 150 patients with vertigo, hearing disturbance, and/or tinnitus. 26 Twenty-three percent of patients with hearing disturbance and 18% of patients with tinnitus had pathologic findings of cervical circulation. Ohinata and colleagues found significantly worse ipsilateral vertebral blood flow in SSNHL patients with hearing loss of more than 50 dB. 27 An important contribution to vascular theory is the article by Schweizer and colleagues. 28 These authors found a higher resistance index in BAs in the acute phase of SSNHL. Similar values were observed after exposure to noise. Young and Lou reported 15 SSNHL cases among patients receiving radiotherapy for nasopharyngeal carcinoma. 29 The authors concluded that SSNHL in these patients is most probably the result of vascular insufficiency, which they proved by MRI findings of radiation necrosis.
Among other possible causes of SSNHL are tumours of the cerebellopontine angle (CPA), especially schwannoma of the eighth nerve. These tumours can lead to SSNHL either by direct nerve compression or by causing vascular obstruction. According to most authors, CPA tumours are rare causes of SSNHL, and among patients with CPA tumour, only 7% have SSNHL. 30 Chaimoff and colleagues reported that among 40 patients with SSNHL, 47% had schwannoma of the eighth nerve. 31 Most authors 32 and our data, however, do not corroborate such a high percentage of CPA pathology in SSNHL patients. Regardless of that, the possibility of a CPA tumour prompts us to be careful in each patient with SSNHL. Meniere's disease can also cause SSNHL. Patients with Meniere's disease are usually easily distinguished from "classic" SSNHL patients with a typical audiometric curve of fluctuating hearing loss, vertiginous disturbances, and tinnitus, which usually occur in attacks followed by symptoms of vegetative system dysfunction. Other causes of SSNHL, such as trauma and neurologic diseases, are rare and can be easily distinguished from idiopathic SSNHL.
Untreated SSNHL has a high tendency toward spontaneous recovery, varying from 30 33 to even 65% 34 in the literature. Because the etiology is unclear and the natural course is frequently favourable, there is confusion regarding treatment of SSNHL in the recent literature (Table 1 ). Guyot and Thielen even claim that SSNHL need not be treated at all. 35 The objective of this study was to assess vertebrobasilar circulation in SSNHL patients, compare the results with a "normal" population, and determine if there is a correlation between vertebrobasilar circulation and hearing in patients treated with pentoxifylline.
Patients and Methods
The study was conducted as a case-control study and included patients with SSNHL who were treated in the Department of Otolaryngology and Head and Neck Surgery, University Hospital "Sestre Milosrdnice," in the period from January 1, 1999, to December 31, 2000. Inclusive criteria encompassed all SSNHL patients admitted within 3 days of onset of the hearing loss. Patients with known causes of hearing loss (such as Meniere's disease, trauma, and tumours) were excluded from this study. Of 54 SSNHL patients, using these criteria, 32 patients were eventually included in the study. The control group consisted of 30 healthy age-and sexmatched persons without evidence of vascular disease or hearing disorder. Because the basic aim of this study was to compare the initial vertebrobasilar circulation in SSNHL patients and that of a normal population, as well as to assess the correlation of vertebrobasilar circulation and hearing level in treated patients, we did not use a placebo-treated control group.
After establishing the initial diagnosis of SSNHL by clinical and audiologic examination, transcranial Doppler (TCD) ultrasonographic measurements of VA and BA flow were performed. TCD ultrasonography and audiologic examinations were performed on the first day, after completion of 10-day therapy, and after 3 months. To rule out other causes of SSNHL, additional diagnostic procedures, such as laboratory tests, brainstem response audiometry, tone decay test, computed tomography (CT), and other procedures, were done, depending on the clinical indication. (Recently, we changed the diagnostic protocol and used magnetic resonance imaging [MRI] instead of CT. The patients in this study did not undergo MRI, which is more sensitive for imaging small intracanalicular tumours. Still, we believe that intracanalicular schwannoma that would cause SSHNL-usually by vascular compression-should be visible on a well-performed CT scan and that we did not miss such a tumour.) Hearing level was calculated as an average loss in decibels in four measured frequencies (500, 1000, 2000, 3000 Hz) according to the guidelines of the American Academy of Otolaryngology-Head and Neck Surgery. This study included 21 female and 11 male patients, with a mean age of 56 years (range 27-78 years). All TCD ultrasonographic measurements were performed by the first author, thus minimizing the potential for interobserver error. Routinely analyzed parameters were systolic, diastolic, and mean blood flow velocity (MBFV) and pulsatility index. Standard values for MBFV were described by Aaslid and colleagues 36 and were adopted in this study. Thus, the normal values for VA and BA MBFV lie in intervals of 26 to 44 cm/s for VAs and 33 to 51 cm/s for BAs, respectively, and those values were considered normal. Values on the edge of this interval (± 2 cm/s) were considered borderline, and values out of this interval were considered pathologic. The patients were assigned to one of the above-mentioned groups according to the TCD ultrasonographic finding of the "worst" vessel (eg, a patient with a normal MBFV in one VA and BA; but pathologic finding in other VA would be considered pathologic). Usually, the findings in all three vessels were consistent.
The treatment protocol for SSNHL was 10 days of Pentilin (pentoxifylline) 300 mg in 500 mL of dextran M 70000 (6% solution) in slow intravenous infusion. This is the standard therapeutic protocol recommended to SSNHL patients in our department. Comparison of MBFV between patients and the control group was done using Student's t-test. The influence of age on TCD ultrasonographic findings and hearing threshold was analyzed using Pearson's coefficient of correlation. The comparison of hearing levels among patients classified by TCD ultrasonographic findings was performed using the Kruskal-Wallis and Mann-WhitneyWilcoxon nonparametric tests.
Results
SSNHL was unilateral in 30 patients (18 on the left side, 12 on the right side) and bilateral in 2 patients. In those 2 patients, the worst side was taken into consideration. Comparison of TCD ultrasonographic values and patients' ages (Figures 1 and 2) shows that with increasing age, there is a slight decrease in MBFV values and more frequent aberrations from normal values. However, this negative correlation between age and MBFV was not significant (Pearson's coefficient of correlation [K] for right VA = -.16, p = .385; for left VA K = -.27, p = .122; and for BA K = -.243, p = .181). The control group also showed an aberration of MBFV values, more frequently in older patients, which was without statistical significance (K = .008, p = .91) (Figure 3) .
Pulsatility index values in this study showed considerable variance; therefore, neither group differed significantly according to the pulsatility index. There was no correlation between age and the amount of hearing loss or recovery rate (Figure 4) (K = -.23, p = .196) .
The division of patients according to TCD ultrasonographic findings gave rise to four groups (according to MBFV values on the onset of SSNHL and after the treatment):
1. Normal: patients with normal TCD ultrasonographic findings before and after treatment 2. Borderline: patients with borderline TCD ultrasonographic findings before and after treatment 3. Pathologic: patients with pathologic TCD ultrasonographic findings before and after treatment 4. Improved: patients with initially pathologic TCD findings, which improved to normal values after therapy There were no "worsened" patients according to the TCD ultrasonographic findings in our study. The average MBFV value in the VAs on the affected side in all patients was 34 cm/s versus 35 cm/s on the healthy side. Student's t-test showed no statistical significance (p = .25). This observation is discussed.
According to the division mentioned above, 13 of 32 patients were considered normal, 8 were considered borderline, 6 were considered pathologic, and 5 were considered to have improved. Figure 5 shows the average hearing improvement after completion of therapy in these four groups.
The average hearing improvement for all treated patients was 12 dB. According to TCD ultrasonographic classification, average hearing improvement was 17 dB in the normal group, 3 dB in the borderline group, 0 dB in the pathologic group, and 28 dB in the improved group. According to the Kruskal-Wallis nonparametric test, the difference among these groups is statistically significant (p = .042).
Six of 32 patients had arterial hypertension, but all of them were regulated by appropriate medication and were normotensive at the onset of disease. According to the TCD ultrasonographic classification, two were normal, two were borderline, and two were pathologic. There was no statistically significant difference in hearing improvement between these patients and the others. During the 10 days of therapy, blood pressure (BP) was routinely monitored three times daily. There was no correlation between BP oscillations and TCD ultrasonographic findings or hearing improvement. The average variation of systolic BP was 19 mm Hg and of diastolic BP was 11 mm Hg. The exception was the group of patients with pathologic TCD ultrasonographic findings who had systolic and diastolic BP variations of 9 and 10 mm Hg, respectively. This difference was not statistically significant (p = .11).
Twenty-one patients had tinnitus as an additonal symptom, and nine patients had vertigo (among them, six had both vertigo and tinnitus). All patients with vertigo described it as a slight imbalance at the beginning of SSNHL that disappeared soon afterward. Only five patients had impairment of the vestibular apparatus according to vestibular functional tests (caloric test and electronystagmography), none of them being new impairment.
When taking tinnitus as the predictor of hearing recovery (regardless of the presence or absence of vertigo), the patients with tinnitus had an average hearing improvement of 10.5 dB, whereas the patients without it improved by 15.5 dB on average (p = .24).
Patients with vertigo (regardless of tinnitus) had an average hearing improvement of 14 dB, and those without it had an improvement of 12 dB (p = .31).
Patients without vertigo and tinnitus had an 18.5 dB improvement on average compared with those with vertigo and/or tinnitus, who had a 14 dB improvement (p = .04).
TCD ultrasonographic findings and hearing levels after 3 months did not differ from the results after 10 days of therapy. The overall results are listed in Table  2 . 16, 17, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] The patients in Table 2 are listed in ascending order according to hearing improvement. Note the visible grouping of "normal" and "improved" TCD ultrasonographic findings in the lower part of the table (connected with better hearing improvement).
Discussion
SSNHL still remains a controversial issue. The definition itself is already confusing because for most patients, the hearing level before the onset of SSNHL is not known, so calculating it as 0 dB (or the same as the unaffected ear) carries some error.
The next problem is the heterogeneity of patients and treatments reported with respect to the way in which the results are presented, which makes the comparison difficult. We use the average of all seven measured frequencies for calculation of hearing level in dB.
Taking into consideration the above, it should not be surprising that whereas most authors treat SSNHL as a medical emergency, 50, 51 some claim that SSNHL should not be treated. 35 In our department, SSNHL is treated as an emergency, and in most patients, therapy begins within 1 or 2 days after onset.
It should be mentioned that some patients recently treated in our department with vasoactive therapy several months after onset of SSNHL had noticeable improvement (there were two patients with average improvement of 10 and 15 dB; these patients were not included in this study). Such patients are important because their hearing improvement can be attributed directly to therapy, whereas among the patients treated immediately after the onset of SSNHL, some would probably improve spontaneously. Therefore, some authors state that the patients eligible for evaluation of the therapy should be those treated at least 4 weeks after the onset of SSNHL. 52 
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When analyzing the MBFV in patients and the control group, it can be seen that in older age, MBFV values are slightly lower and extreme values (whether high or low) are more frequent. Although not statistically significant, this observation suggests a possible need for age-dependent correction of standard MBFV values. When analyzing average initial hearing loss and recovery, one can even see somewhat worse impairments in younger patients. From this it can be concluded that age is not a risk factor for SSNHL, regardless of its etiology.
In this study, we divided patients according to MBFV values into three categories (normal, borderline, and pathologic findings). The criterion for placement in a category was the worst MBFV finding, regardless of the vessel (ie, BA, right or left VA). The reason for this is that the LA is usually a branch of the BA and sometimes can be a branch of the anterior inferior cerebellar artery, which is a branch of the VA. Because, without an invasive arteriographic test, we do not know which is the exact origin of the LA and because both VAs contribute evenly to BA blood flow, we treated the findings on ipsilateral or contralateral VAs equally ( Table 3) . The main reason for dividing the patients into qualitative groups according to MBFV is that a higher valuethe one exceeding the normal range-does not mean better circulation. On the contrary, it usually signifies stenosis of the observed vessel segment.
Borderline and pathologic TCD ultrasonographic findings were found more frequently in SSNHL patients than in the control population (Table 4) . This observation itself already points to a connection between vertebrobasilar circulation and SSNHL.
Probably the most important observation in this study is the correlation between TCD ultrasonographic findings and hearing recovery after therapy. Patients with a normal MBFV had better hearing recovery (17 dB) than those with borderline or pathologic values (3 and 0 dB, respectively). The best recovery occurred in five patients whose initial pathologic TCD ultrasonographic findings also improved after therapy (28 dB). This observation leads to the conclusion that SSNHL has a vascular etiology, at least in some patients, and in those patients, vasoactive therapy is justified. It can be speculated that the etiology is also vascular in (some) patients with borderline and pathologic TCD ultrasonographic findings, but because their circulation did not improve after therapy, they did not recover their hearing. Nevertheless, good circulation is mandatory for recovery regardless of the causative agent that led to impairment. There are several possible causes of impaired MBFV. One possible cause is the rheologic parameters of blood (ie, viscosity that could be influenced by the number and shape of blood cells and other soluble particles contained in the blood). BP and arterial resistance can also change MBFV. We did not find significant changes in BP in our patients, but those changes can also be local (ie, affecting only some vessels). The resulting decreased blood flow in the cochlea is not necessarily the only cause of hearing impairment. It can render the cochlea more susceptible to other etiologic causes, such as viruses and toxins.
According to most authors, tinnitus and vertigo, when present in SSNHL, are unfavourable prognostic signs for hearing recovery. 53 Our results meet those observations, except that isolated tinnitus and isolated vertigo were not significant predictors of worse recovery. In this study, patients with vertigo had even slightly better improvement than patients without vertigo (14 vs 12 dB; not statistically significant). It should be noted that tinnitus is mostly a subjective complaint, as was the vertigo in our group of patients, because none of them had fresh vestibular impairment.
The mechanisms involved in the translation from sound to neural impulse are complex and still not completely resolved. Numerous components of this mechanical-electrical transformation must function perfectly for normal hearing (ie, quality and amount of peri-and endolymphatic fluid, tectorial membrane and its components, sensory and pilar cells, proper oxygen and metabolite delivery, adequate circulation, eighth nerve function). Loss of any of these components can lead to hearing impairment. It is therefore clear that SSNHL should be treated as a symptom, not as a disease, and 16, 17, [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] Naturally, in some patients, the loss of hearing function may be irreversible, meaning that no therapy can lead to improvement.
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Perhaps the better overall recovery in SSNHL patients could be accomplished if each patient was treated according to the supposed etiology. A potential algorithm for SSNHL therapy should include at least three of the most frequently mentioned etiopathogenetic mechanisms (ie, viral, vascular, and autoimmune) and treat the patients accordingly with either antiviral, vasoactive, or immunosuppressive agents. Such a trial should be multicentric to collect an adequate number of patients for evaluation of results. 
